Lupus Nephritis Market to Extend at a CAGR of 8.4% by 2032 | DelveInsight

August 31 22:03 2022
Lupus Nephritis Market to Extend at a CAGR of 8.4% by 2032 | DelveInsight

DelveInsight’s Lupus Nephritis Market Insights report proffers a detailed comprehension of the lupus nephritis market size by treatment, epidemiology, emerging therapies, lupus nephritis market share of the individual therapies, current and forecasted lupus nephritis market size from 2019 to 2032 segmented into 7MM (the United States, EU5 [Germany, France, Italy, Spain, and the United Kingdom], and Japan).

 

The Lupus Nephritis market is anticipated to show positive growth owing to factors such as increasing prevalence, strong pipeline activity, and the presence of multiple Large-Cap Pharma players.

 

Key features from the Lupus Nephritis Market report:

  • As per DelveInsight’s analysis, the total lupus nephritis market in the 7MM is expected to grow at a CAGR of 8.4% during the study period 2019-2032.
  • Key companies currently working in the market include names such as Aurinia Pharmaceuticals, Roche, AstraZeneca, Boehringer Ingelheim, Novartis, Novartis Pharmaceuticals, Hoffmann-La Roche, Janssen Research & Development, BeiGene, Suzhou Suncadia Biopharmaceuticals Co., Ltd., Alexion Pharmaceuticals, Omeros Corporation, Corestem, Inc., Bristol-Myers Squibb, Boehringer Ingelheim, Apellis Pharmaceuticals, AstraZeneca, Kezar Life Sciences, Equillium, Eledon Pharmaceuticals, Resolve Therapeutics, and others.
  • The lupus nephritis pipeline therapies include GAZYVA, Saphnelo (Anifrolumab), Iscalimab, Cosentyx, Zanubrutinib, Ravulizumab, Anifrolumab, Itolizumab, and others that are expected to launch in the upcoming years.
  • As per our estimates, the total lupus nephritis market size in the United States accounted for USD 975.1 million in 2021, which is likely to rise during the study period.

 

Download Sample Report- https://www.delveinsight.com/sample-request/lupus-nephritis-market

 

Lupus Nephritis Overview

Lupus Nephritis is a common and potentially devastating exhibitionof systemic lupus erythematosus. It is a leading cause of morbidity and mortality in patients with SLE. LN leads to inflammation of small blood vessels which play an essential role in filtering waste materials in the kidney. It also involves the inflammation of glomeruli.

 

Lupus Nephritis Epidemiology Segmentation in the 7MM

  • Lupus Nephritis Prevalent population
  • Total Lupus Nephritis diagnosed population
  • Lupus Nephritis Gender-specific prevalent population
  • Lupus Nephritis Class-Specific cases
  • Lupus Nephritis Clinical manifestations

 

Lupus Nephritis Treatment Market

The lupus nephritis treatment landscape currently has some approved therapies, while the principal goal of the present treatment regimen is to normalize renal function or, at least, prevent the progressive loss of renal function. However, therapy differs depending on the pathologic lesion. The lupus nephritis treatment strategies briefly emphasize the maximal preservation of renal function and patient protection from long-term consequences, mainly end-stage renal disease (ESRD) requiring dialysis or renal transplantation. In general, the mainstays for addressing lupus nephritis are mainly dominated by glucocorticosteroids (prednisone or methylprednisolone), immunosuppressants (cyclophosphamide, azathioprine, mycophenolate mofetil (MMF), others (monoclonal antibodies, such as rituximab), and adjunctive therapies (such as hydroxychloroquine, angiotensin-converting enzyme (ACE) inhibitor, angiotensin receptor blockers, etc.).

 

Lupus Nephritis Treatment landscape

Talking about the emerging lupus nephritis treatment landscape, several companies, including Roche, Novartis, AstraZeneca, and Boehringer Ingelheim, are eyeing the existing untapped market of lupus nephritis and trying their best to grab a significant market share in the 7MM. Some of the emerging therapies had already demonstrated positive late-stage results among the lupus nephritis-affected individuals.

 

Key Lupus Nephritis Pipeline Therapies and Companies

  • GAZYVA: Roche
  • Saphnelo (Anifrolumab): AstraZeneca
  • Iscalimab: Novartis
  • Cosentyx: Novartis
  • Zanubrutinib: BeiGene
  • Ravulizumab: Alexion Pharmaceuticals
  • Anifrolumab: AstraZeneca
  • Itolizumab: Equillium

 

Lupus Nephritis Market Drivers and Barriers

Factors responsible for the anticipated growth in the lupus nephritis market include the increasing prevalence of this disease assisted by organizational support and a promising pipeline constituting late-stage products that are expecting their approval. Other additional factors are extensive research and development, awareness, and a surge in the number of clinical studies contributing to the lupus nephritis market growth. On the contrary, several aspects such as a high cost of treatment, the need for novel therapeutics as well as a need for a targeted treatment regimen can all serve as potential lupus nephritis market drawbacks.

 

Scope of the Lupus Nephritis Market Report

  • Study period: 2019–2032
  • Coverage: 7MM (The United States, EU5 [Germany, France, Italy, Spain, and the United Kingdom], and Japan)
  • Key lupus nephritis companies: Aurinia Pharmaceuticals, Roche, AstraZeneca, Boehringer Ingelheim, Novartis, Novartis Pharmaceuticals, Hoffmann-La Roche, Janssen Research and Development, BeiGene, Suzhou Suncadia Biopharmaceuticals Co., Ltd., Alexion Pharmaceuticals, Omeros Corporation, Corestem, Inc.,  Bristol-Myers Squibb, Boehringer Ingelheim, Apellis Pharmaceuticals, AstraZeneca,  Kezar Life Sciences, Equillium, Eledon Pharmaceuticals, Resolve Therapeutics, and others
  • Key  lupus nephritis pipeline therapies: GAZYVA, Saphnelo (Anifrolumab), Iscalimab, Cosentyx, Zanubrutinib, Ravulizumab, Anifrolumab, Itolizumab, and others
  • Therapeutic assessment:  lupus nephritis current marketed and emerging therapies
  • Market dynamics:  lupus nephritis market drivers and barriers
  • Competitive intelligence analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Unmet Needs, KOL’s views, Analyst’s views, Market Access and Reimbursement

 

Request Sample Report- https://www.delveinsight.com/sample-request/lupus-nephritis-market

 

Table of content

1. Key Insights

2. Executive Summary

3. Lupus Nephritis: Market Overview at a Glance

4. Lupus Nephritis: Disease Background and Overview

5. Epidemiology and Patient Population

6. 7MM Total Prevalent Patient Population of LN

7. Country Wise-Epidemiology of Lupus Nephritis

8. Treatment

9. Unmet Needs

10. Patient Journey

11. Case Studies

12. Marketed Therapies

13. Key Cross Competitors

14. Emerging Therapies

15. Other Promising Candidates

16. Lupus Nephritis: 7 Major Market Analysis

17. United States Lupus Nephritis Market Outlook

18. EU-5 Countries: Lupus Nephritis Market Outlook

19. Japan: Lupus Nephritis Market Outlook

20. Lupus Nephritis Market Drivers

21. Lupus Nephritis Market Barriers

22. SWOT Analysis

23. Market Access and Reimbursement

24. Appendix

25. DelveInsight Capabilities

26. Disclaimer

27. About DelveInsight

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/